Alvespimycin hydrochloride
Code | Size | Price |
---|
TAR-T6297-5mg | 5mg | £98.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6297-10mg | 10mg | £114.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6297-1mL | 1 mL * 10 mM (in DMSO) | £116.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6297-25mg | 25mg | £149.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6297-50mg | 50mg | £209.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
17-DMAG is a potent HSP90 inhibitor with IC50 of 62 nM. Phase 2.
CAS:
467214-21-7
Formula:
C32H49ClN4O8
Molecular Weight:
653.21
Pathway:
Metabolism; Cytoskeletal Signaling; Apoptosis
Purity:
0.9994
SMILES:
Cl.CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)C(C)=CC=C/[C@H](OC)[C@@H](OC(N)=O)C(C)=C[C@H](C)[C@H]1O)C2=O
Target:
Apoptosis; HSP
References
Henke A, et al. Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90. Cancers (Basel). 2016 Aug 24;8(9). pii: E77.
Schwock J, et al. Cancer Res, 2009, 69(11), 4750-4759.
Rao R, et al. Cancer Biol Ther, 2009, 8(13), 1273-1280.
Hertlein E, et al. Blood, 2010, 116(1), 45-53.
Ge J, et al. J Med Chem, 2006, 49(15), 4606-4615.
Lang SA, et al. Mol Cancer Ther, 2007, 6(3), 1123-1132.